Completed PHASE3 INTERVENTIONAL 1-arm NCT00163189

Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm

Evolution Of Growth Rate In Children With Growth Retardation Related To Long-term Corticotherapy And Treated By Genotonorm

Sponsor: Pfizer

Conditions Growth Hormone Deficiency

Interventions Somatropin

Updated 8 times since 2017 Last updated: Feb 19, 2024 Started: Jan 31, 2005 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Growth Hormone Deficiency, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amiens, France , Annemasse, France , Besançon, France , Bron, France , Clermont-Ferrand, France , Grenoble, France , Marseille, France , Montpellier, France , Nantes, France , Nice, France and 6 more locations